Prelude Capital Management, LLC Spero Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.74 - $7.44 $7,937 - $79,801	10,726 New	10,726 $8,000
Q4 2020 Feb 16, 2021	SELL	$11.65 - $22.07 $3,495 - $6,621	-300 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.96 - $14.12 $1,792 - $2,824	200 Added 200.0%	300 $3,000
Q2 2020 Aug 14, 2020	SELL	$7.27 - $14.18 $4,362 - $8,508	-600 Reduced 85.71%	100 $1,000
Q1 2020 May 15, 2020	SELL	$5.27 - $10.41 $1,054 - $2,082	-200 Reduced 22.22%	700 $6,000
Q4 2019 Feb 14, 2020	BUY	$9.46 - $12.16 $1,892 - $2,432	200 Added 28.57%	900 $9,000
Q3 2019 Nov 14, 2019	BUY	$9.01 - $12.55 $1,802 - $2,510	200 Added 40.0%	700 $7,000
Q2 2019 Aug 14, 2019	BUY	$10.25 - $14.36 $5,125 - $7,180	500 New	500 $6,000

14.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $27M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.